B-cell frequencies and immunoregulatory phenotypes in myeloproliferative neoplasms: Influence of ruxolitinib, interferon-α2, or combination treatment.
Anders Lindholm SørensenMads Emil BjørnCaroline H RileyMorten HolmstrømMads Hald AndersenInge Marie SvaneStine Ulrik MikkelsenVibe SkovLasse KjaerHans Carl HasselbalchClaus H NielsenPublished in: European journal of haematology (2019)
B-cell frequency and phenotype were altered in MPN patients. Ruxolitinib therapy had marked effects on both frequency and phenotype.